Amazon's $200 Billion Bet: Satellite Deals and AI Labs Fuel a High-Stakes Quarter

Amazon's Q1 2026 results hinge on massive AI & satellite investments. AWS AI revenue hits $15B run rate as $11.6B Globalstar deal targets smartphone connectivity.

Amazon's stock, trading at €211.20, is riding a wave of momentum, having surged nearly 15% in the past month. Yet this rally masks a fundamental tension as the company prepares to report first-quarter 2026 results on April 30. Investors are weighing staggering capital expenditures against explosive growth in artificial intelligence and a bold new move into satellite communications.

The tech giant's aggressive spending plans are a primary focus. For its 2026 fiscal year, Amazon has earmarked nearly $200 billion in capital investments, a figure that recently pressured its free cash flow down to $11.2 billion after a $50.7 billion spike in capital expenditures. Analysts are watching closely to see if the massive outlay will generate a positive operating leverage.

A significant portion of this investment is flowing into the artificial intelligence infrastructure of Amazon Web Services (AWS). The cloud division is already generating an annualized revenue run rate exceeding $15 billion from AI services. In tandem, Amazon's in-house chip business is booming, securing a crucial competitive edge with a $20 billion revenue run rate and triple-digit growth percentages. The strategy hinges on maintaining high utilization of its cloud data centers; empty server racks could lead to massive depreciation charges that would weigh heavily on profits.

Beyond the cloud, Amazon is aggressively expanding into new verticals. Its healthcare initiative is now delivering Eli Lilly's newly approved weight-loss drug, Foundayo, directly to customers' doors. The Amazon Pharmacy service launched with same-day delivery in nearly 3,000 cities, with plans to expand to 4,500 locations by year-end. Through its integrated model, Amazon One Medical handles the clinical evaluation and prescription, while the pharmacy division manages fulfillment, vastly expanding the company's addressable market beyond traditional e-commerce.

In a single, sweeping move, Amazon recently announced the acquisition of satellite operator Globalstar for $11.6 billion. Shareholders are being offered $90 per share in cash or Amazon stock—a premium of roughly 117% over Globalstar's late-October price. With 58% of voting rights already committed, the deal is slated to close in 2027. The acquisition's true value lies in Globalstar's globally harmonized L-Band and S-Band frequency licenses across more than 120 countries. These spectrum rights, which enable direct-to-device smartphone connectivity without special hardware, are nearly impossible to replicate and come with 24 worldwide ground stations and a ready-made operational infrastructure.

Crucially, the deal brings Apple on board as a flagship partner. Amazon and Apple have agreed that Amazon's Project Kuiper satellite network, known as Leo, will power satellite services for the iPhone and Apple Watch, including Emergency SOS via satellite. Apple, which had previously invested about $1.5 billion in Globalstar, secures continuity for its safety features. The partnership paves the way for future services like Apple Maps via satellite and a satellite API for third-party developers, upgrades that Amazon will now control.

This move attempts to close a formidable gap with rival SpaceX's Starlink, which operates roughly 10,000 satellites and serves over 9 million subscribers. Amazon Leo has only about 200 satellites in orbit and has yet to launch a consumer service. The Globalstar acquisition provides the essential direct device connectivity needed to reach a mass market.

Simultaneously, AWS launched a new platform named Amazon Bio Discovery, an AI tool designed to accelerate early-stage drug discovery by allowing scientists to run complex computations without programming skills. Early users include Bayer, the Broad Institute, and Voyager Therapeutics. The move builds on a strong foundation, as 19 of the world's 20 largest pharmaceutical companies already use AWS services.

Wall Street is positioning for the upcoming earnings. While Goldman Sachs slightly trimmed its price target from $280 to $275, it reaffirmed its buy rating, with analyst Eric Sheridan highlighting the risks of this next growth phase. Needham has also urged caution regarding the aggressive capital strategy. Roth Capital, following the satellite deal announcement, reiterated its buy recommendation with a $285 price target.

For Q1 2026, Amazon has guided for revenue between $173.5 and $178.5 billion, representing growth of up to 15% year-over-year. Operating income is projected to land between $16.5 and $21.5 billion. When the books open on April 30, investor scrutiny will center on four key metrics: AWS growth rates, the impact of rising energy costs on logistics, the timeline for Project Kuiper, and margins in the advertising business. The company's ability to demonstrate that its historic investments are paying off will likely set the tone for its stock performance throughout the rest of the year.